RHBDF2 and esophageal squamous cell carcinoma: An activating mutation of iRhom2, identified in TOC patients, results in palmar and plantar hyperkeratosis, accelerated wound healing, oral leukoplakia, and a markedly elevated risk of developing esophageal squamous cell carcinoma.